R&D Pipeline

Our Pipeline and Its Potential

Beyond Air Pipeline & Market Size

Product Indication Development
Status
Key Dates(1) US Sales
Potential(2)
Worldwide Sales
Potential(2)
LungFitPH
Ventilator compatible
In-Hospital use for PPHN and cardiac surgery PMA Pending US Launch 2Q21

CE Mark 2H21
>$300M >$600M
LungFit PRO Acute viral pneumonia (including COVID-19) Pilot studies in progress Interim data Spring 2021 N/A N/A
LungFit PRO Bronchiolitis 3 Pilot studies complete

Pivotal-ready
Pivotal Starts 4Q21

(pandemic permitting)

US Launch 2023
>$500M

Beyond Air to commercialize
>$1.2B
LungFit GO Nontuberculous mycobacteria (NTM) lung infection Pilot phase Interim data mid-2021

Self-administration at home
>$1B >$2.5B
LungFit GO Severe exacerbations due to lung infections in COPD patients Pre-clinical Pilot study start 2H21 >$2.5B >$6B
Solid Tumors Multiple solid tumors Pre-clinical New in vivo data
to be presented 4Q20
TBD TBD

†Caution - LungFit is an Investigational Device, Limited by Federal (or United States) Law to Investigational Use.

(1) All dates are based on projections and appropriate financing, anticipated first launch on a global basis pending appropriate regulatory approvals

(2) All figures are Company estimates for peak year sales: Global sales potential includes US sales potential

Important Safety Information

Caution - LungFit is an Investigational Device, Limited by Federal (or United States) Law to Investigational Use.